Anzeige
Mehr »
Mittwoch, 27.08.2025 - Börsentäglich über 12.000 News
Breaking: AlsetAI zündet nächste Stufe - Neue Allianz mit CHIP Datacentres & Hochkarätige Vorstände markieren Wendepunkt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JRKN | ISIN: KYG0520K1094 | Ticker-Symbol: 2VJ
Tradegate
26.08.25 | 10:02
1,590 Euro
+2,58 % +0,040
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ASCLETIS PHARMA INC Chart 1 Jahr
5-Tage-Chart
ASCLETIS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,5101,59026.08.
1,5001,59026.08.

Aktuelle News zur ASCLETIS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN4
MoASCLETIS-B (01672): COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE-
19.08.ASCLETIS-B Opens ~10% Lower, Raises $470M via 9.9% Discounted Top-up Shr Placement2
19.08.ASCLETIS-B Aims to Raise HKD468M Net w/Top-up Placing at 9.9% Discount; Controlling Shareholders Net HKD388M4
19.08.ASCLETIS-B (01672): (1) PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE AND (2) SALE OF SHARES BY THE TOP-UP ...5
18.08.Ascletis Pharma Inc.: Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an ...87- Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction...
► Artikel lesen
18.08.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES THE COMBINATION OF ASC47 AND ASC31, ITS DUAL GLP-1R/GIPR PEPTIDE AGONIST, DEMONSTRATED ...2
15.08.ASCLETIS-B (01672): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 20252
ASCLETIS PHARMA Aktie jetzt für 0€ handeln
13.08.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES ASC47, A MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE FOR TREATMENT OF OBESITY, DEMONSTRATED ...7
05.08.Ascletis Pharma Inc.: Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight225- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants...
► Artikel lesen
05.08.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE IIA STUDY FOR ITS SMALL MOLECULE ORAL GLP-1R AGONIST, ASC30, ...3
28.07.Ascletis Pharma Inc.: Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30124- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly...
► Artikel lesen
28.07.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PARTICIPANTS WITH OBESITY OR OVERWEIGHT DOSED IN ITS U.S. 12-WEEK PHASE IIA STUDY ...1
21.07.ASCLETIS-B (01672): NOTICE OF BOARD MEETING3
15.07.Ascletis Pharma Inc.: Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRß Agonist, ASC47, and Semaglutide for the Treatment of ...138- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of...
► Artikel lesen
15.07.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES DOSING OF ALL PARTICIPANTS IN ITS U.S. CLINICAL STUDY COMBINING ADIPOSE-TARGETED, ONCE-MONTHLY ...3
03.07.Ascletis Pharma Inc.: Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30144- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of small molecule...
► Artikel lesen
03.07.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PARTICIPANTS WITH OBESITY OR OVERWEIGHT DOSED IN A U.S. 13-WEEK PHASE IIA STUDY ...6
30.06.ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE: THIRD-PARTY PETITION FILED AGAINST THE COMPANY'S U.S. PATENT3
27.06.ASCLETIS-B (01672): NOMINATION COMMITTEE - TERMS OF REFERENCE2
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2